ALDX Logo

Aldeyra Therapeutics, Inc. (ALDX) 

NASDAQ
Market Cap
$295.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
95 of 963
Rank in Industry
72 of 552

Largest Insider Buys in Sector

ALDX Stock Price History Chart

ALDX Stock Performance

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Insider Activity of Aldeyra Therapeutics, Inc.

Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $2.77M and sold $851,621 worth of Aldeyra Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $12.36M and sold $2.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $49.83M.

The last purchase of 37,712 shares for transaction amount of $178,755 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑05.

List of Insider Buy and Sell Transactions, Aldeyra Therapeutics, Inc.

2024-08-12SaleChief Development Officer
16,041
0.0272%
$4.74$75,975+12.84%
2024-08-12SaleSee Remarks
10,834
0.0184%
$4.74$51,313+12.84%
2024-04-05Purchase10 percent owner
37,712
0.0643%
$4.74$178,755-6.57%
2024-04-04Purchase10 percent owner
140,281
0.2374%
$4.67$655,112-5.56%
2024-04-03Purchase10 percent owner
309,847
0.5185%
$4.09$1.27M+6.75%
2024-04-02Purchase10 percent owner
186,051
0.3061%
$3.44$640,015+24.51%
2024-04-01Purchase10 percent owner
8,374
0.0141%
$3.25$27,216+34.86%
2024-03-12SalePresident and CEO
85,324
0.147%
$3.05$260,238+40.03%
2024-03-12SaleChief Development Officer
11,537
0.0206%
$3.16$36,503+40.03%
2024-03-11SalePresident and CEO
97,914
0.1675%
$3.27$320,521+29.54%
2024-03-11SaleChief Development Officer
18,231
0.0324%
$3.41$62,102+29.54%
2024-03-11SaleSee Remarks
13,201
0.0235%
$3.41$44,968+29.54%
2023-10-18Sale10 percent owner
306,499
0.5276%
$1.74$533,308+109.83%
2023-10-16Sale10 percent owner
2.45M
3.6657%
$1.60$3.92M+98.09%
2023-04-12Purchasedirector
509
0.0009%
$10.13$5,156
2022-08-09Purchase
15,000
0.027%
$7.85$117,750-4.83%
2022-08-08Purchase
97,000
0.1669%
$7.24$702,280-1.53%
2022-08-05Purchase
141,000
0.2422%
$6.95$979,950+2.46%
2022-08-04Purchase
95,100
0.1609%
$6.17$586,767+13.46%
2022-08-03Purchase
100,000
0.1722%
$5.84$584,000+21.64%

Insider Historical Profitability

18.59%
PERCEPTIVE ADVISORS LLC10 percent owner
9275851
15.5767%
$4.97182+4.58%
Brady Todd CPresident and CEO
1471298
2.4707%
$4.97112+8.55%
Machatha StephenChief Development Officer
236771
0.3976%
$4.9703
Greenberg BruceSee Remarks
126382
0.2122%
$4.9702
EDELMAN JOSEPH
11350085
19.0599%
$4.9790+19.29%
DOUGLAS RICHARDdirector
125000
0.2099%
$4.9770+43%
Reed JoshuaChief Financial Officer
35774
0.0601%
$4.9710+5.74%
JOYCE MARTIN JOSEPH
23967
0.0402%
$4.9750+39.85%
Bronstein Bendirector
18644
0.0313%
$4.9730+4.21%
Clark David JChief Medical Officer
17878
0.03%
$4.9710+8.52%
Clarke C. Boyddirector
15500
0.026%
$4.9720+69.19%
Phillips Gary M.director
9375
0.0157%
$4.9710+20.66%
TREU JESSE Idirector
8763
0.0147%
$4.9701
Walker Nealdirector
6250
0.0105%
$4.9710+20.66%
McMullin DavidChief Commerical Officer
6148
0.0103%
$4.9710+5.74%
Tulipano Stephen JChief Financial Officer
3333
0.0056%
$4.9710+0.98%
Miller-Rich Nancydirector
922
0.0015%
$4.9720

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$28.1M14.468.59M0%+$00.02
Tupelo Capital Management LLC$17.9M9.225.48M0%+$00.44
The Vanguard Group$12.65M6.513.87M-1.49%-$191,353.86<0.0001
BlackRock$10.83M5.573.31M-3.5%-$392,357.51<0.0001
Kennedy Capital Management Inc$4.31M2.221.32M+3.29%+$137,369.430.09
Geode Capital Management$3.36M1.731.03M+0.55%+$18,399.16<0.0001
HERITAGE ASSET MANAGEMENT INC$3.16M1.63967,815-4.21%-$139,037.130.02
Verition Fund Management Llc$3.08M1.58940,398-29.02%-$1.26M0.03
State Street$3.07M1.58939,569+4.51%+$132,631.22<0.0001
Dimensional Fund Advisors$2.88M1.49882,210-15.06%-$511,565.39<0.01
Renaissance Technologies$2.38M1.23727,690+142.56%+$1.4M<0.01
D. E. Shaw & Co.$1.79M0.92547,640+110.58%+$940,399.79<0.01
Acadian Asset Management$1.48M0.76452,449+106.33%+$761,685.370.01
Bank of America$1.3M0.67398,951+6.69%+$81,851.32<0.0001
Northern Trust$1.27M0.66389,187-0.97%-$12,491.40<0.0001
Millennium Management LLC$1.27M0.65388,705-11.74%-$169,003.36<0.01
Wells Fargo$1.27M0.65387,304+12.22%+$137,964.56<0.0001
Los Angeles Capital Management LLC$1.25M0.64380,773+240.85%+$879,829.68<0.01
Two Sigma Advisers LP$1.23M0.63374,900+6.69%+$76,845.00<0.01
Morgan Stanley$1.14M0.59349,546-16.79%-$230,606.86<0.0001
Johnson & Johnson$979,918.000.5299,6690%+$00.02
Deutsche Bank$956,105.000.49292,387-1.7%-$16,510.22<0.0001
Two Sigma$781,412.000.4238,964+18.57%+$122,373.17<0.01
Palo Alto Investors Lp$737,271.000.38225,4650%+$00.08
Jacobs Levy Equity Management$585,065.000.3178,919New+$585,065.00<0.01
Woodstock Corporation$558,238.000.29170,715+46.28%+$176,615.950.06
BNY Mellon$525,938.000.27160,837-5.41%-$30,090.60<0.0001
Nuveen$424,197.000.22129,7240%+$0<0.0001
Ameriprise Financial$412,595.000.21126,176-23.96%-$129,988.88<0.0001
Charles Schwab$410,467.000.21125,5250%+$0<0.0001
Sherbrooke Park Advisers Llc$352,336.000.18107,748New+$352,336.000.07
AQR Capital$343,527.000.18105,054New+$343,527.00<0.01
Simplex Trading Llc$305,000.000.1693,465+333.15%+$234,585.510.01
Goldman Sachs$299,915.000.1591,717-37.81%-$182,345.26<0.0001
Ohio Strs$269,000.000.1482,300-5.94%-$16,996.35<0.01
RhumbLine Advisers$209,512.000.1164,074+3.57%+$7,229.63<0.0001
Cornercap Investment Counsel Inc$201,435.000.161,6010%+$00.03
International Assets Investment Management Llc$197,181.000.160,300+3.08%+$5,886.00<0.01
Citadel Advisors LLC$180,661.000.0955,248-18.43%-$40,812.88<0.0001
AllianceBernstein$164,939.000.0950,4400%+$0<0.0001
T. Rowe Price$158,000.000.0848,273+7.69%+$11,278.93<0.0001
UBS$157,993.000.0848,316-8.97%-$15,568.44<0.0001
Denali Advisors$154,671.000.0847,300New+$154,671.000.05
Susquehanna International Group$130,529.000.0739,917-80.26%-$530,654.00<0.0001
Squarepoint Ops LLC$124,891.000.0638,193-47.66%-$113,701.07<0.0001
Raymond James Associates$117,798.000.0636,024+9.88%+$10,594.76<0.0001
First Manhattan Co.$113,616.000.0634,7450%+$0<0.0001
Barclays$106,000.000.0632,487-49.12%-$102,348.88<0.0001
Invesco$104,071.000.0531,826+0.19%+$199.47<0.0001
Joseph P. Lucia & Associates LLC$92,384.000.0528,2520%+$00.06
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.